237 related articles for article (PubMed ID: 17283154)
1. A single-chain Fv diabody against human leukocyte antigen-A molecules specifically induces myeloma cell death in the bone marrow environment.
Sekimoto E; Ozaki S; Ohshima T; Shibata H; Hashimoto T; Abe M; Kimura N; Hattori K; Kawai S; Kinoshita Y; Yamada-Okabe H; Tsuchiya M; Matsumoto T
Cancer Res; 2007 Feb; 67(3):1184-92. PubMed ID: 17283154
[TBL] [Abstract][Full Text] [Related]
2. 2D7 diabody bound to the alpha2 domain of HLA class I efficiently induces caspase-independent cell death against malignant and activated lymphoid cells.
Kimura N; Kawai S; Kinoshita Y; Ishiguro T; Azuma Y; Ozaki S; Abe M; Sugimoto M; Hirata Y; Orita T; Okabe H; Matsumoto T; Tsuchiya M
Biochem Biophys Res Commun; 2004 Dec; 325(4):1201-9. PubMed ID: 15555554
[TBL] [Abstract][Full Text] [Related]
3. Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma.
Tassone P; Neri P; Burger R; Savino R; Shammas M; Catley L; Podar K; Chauhan D; Masciari S; Gozzini A; Tagliaferri P; Venuta S; Munshi NC; Anderson KC
Clin Cancer Res; 2005 Jun; 11(11):4251-8. PubMed ID: 15930364
[TBL] [Abstract][Full Text] [Related]
4. Apoptosis inducing bivalent single-chain antibody fragments against CD47 showed antitumor potency for multiple myeloma.
Kikuchi Y; Uno S; Kinoshita Y; Yoshimura Y; Iida S; Wakahara Y; Tsuchiya M; Yamada-Okabe H; Fukushima N
Leuk Res; 2005 Apr; 29(4):445-50. PubMed ID: 15725479
[TBL] [Abstract][Full Text] [Related]
5. IFN-gamma enhances the antimyeloma activity of the fully human anti-human leukocyte antigen-DR monoclonal antibody 1D09C3.
Carlo-Stella C; Guidetti A; Di Nicola M; Lavazza C; Cleris L; Sia D; Longoni P; Milanesi M; Magni M; Nagy Z; Corradini P; Carbone A; Formelli F; Gianni AM
Cancer Res; 2007 Apr; 67(7):3269-75. PubMed ID: 17409435
[TBL] [Abstract][Full Text] [Related]
6. Effective induction of cell death on adult T-cell leukaemia cells by HLA-DRbeta-specific small antibody fragment isolated from human antibody phage library.
Muraoka S; Ito Y; Kamimura M; Baba M; Arima N; Suda Y; Hashiguchi S; Torikai M; Nakashima T; Sugimura K
J Biochem; 2009 Jun; 145(6):799-810. PubMed ID: 19270058
[TBL] [Abstract][Full Text] [Related]
7. Anti-CD54 (ICAM-1) has antitumor activity in SCID mice with human myeloma cells.
Huang YW; Richardson JA; Vitetta ES
Cancer Res; 1995 Feb; 55(3):610-6. PubMed ID: 7834632
[TBL] [Abstract][Full Text] [Related]
8. A bivalent single-chain Fv fragment against CD47 induces apoptosis for leukemic cells.
Kikuchi Y; Uno S; Yoshimura Y; Otabe K; Iida S; Oheda M; Fukushima N; Tsuchiya M
Biochem Biophys Res Commun; 2004 Mar; 315(4):912-8. PubMed ID: 14985099
[TBL] [Abstract][Full Text] [Related]
9. CD74 is expressed by multiple myeloma and is a promising target for therapy.
Burton JD; Ely S; Reddy PK; Stein R; Gold DV; Cardillo TM; Goldenberg DM
Clin Cancer Res; 2004 Oct; 10(19):6606-11. PubMed ID: 15475450
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-18 inhibits lodging and subsequent growth of human multiple myeloma cells in the bone marrow.
Yamashita K; Iwasaki T; Tsujimura T; Sugihara A; Yamada N; Ueda H; Okamura H; Futani H; Maruo S; Terada N
Oncol Rep; 2002; 9(6):1237-44. PubMed ID: 12375027
[TBL] [Abstract][Full Text] [Related]
11. Anti-CD74 antibody-doxorubicin conjugate, IMMU-110, in a human multiple myeloma xenograft and in monkeys.
Sapra P; Stein R; Pickett J; Qu Z; Govindan SV; Cardillo TM; Hansen HJ; Horak ID; Griffiths GL; Goldenberg DM
Clin Cancer Res; 2005 Jul; 11(14):5257-64. PubMed ID: 16033844
[TBL] [Abstract][Full Text] [Related]
12. Bone marrow stromal cell interaction reduces syndecan-1 expression and induces kinomic changes in myeloma cells.
Fuhler GM; Baanstra M; Chesik D; Somasundaram R; Seckinger A; Hose D; Peppelenbosch MP; Bos NA
Exp Cell Res; 2010 Jul; 316(11):1816-28. PubMed ID: 20307537
[TBL] [Abstract][Full Text] [Related]
13. Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo.
Mitsiades CS; Ocio EM; Pandiella A; Maiso P; Gajate C; Garayoa M; Vilanova D; Montero JC; Mitsiades N; McMullan CJ; Munshi NC; Hideshima T; Chauhan D; Aviles P; Otero G; Faircloth G; Mateos MV; Richardson PG; Mollinedo F; San-Miguel JF; Anderson KC
Cancer Res; 2008 Jul; 68(13):5216-25. PubMed ID: 18593922
[TBL] [Abstract][Full Text] [Related]
14. Constitutive expression of IL-6-LIKE cytokines in normal bone marrow: implications for pathophysiology of myeloma.
Barton BE; Murphy TF
Cytokine; 2000 Oct; 12(10):1537-45. PubMed ID: 11023670
[TBL] [Abstract][Full Text] [Related]
15. Requirement of soluble factors produced by bone marrow stromal cells on the growth of novel established human myeloma cell line.
Aikawa S; Hatta Y; Tanaka M; Kaneita Y; Yasukawa K; Sawada U; Horie T; Tsuboi I; Aizawa S
Int J Oncol; 2003 Mar; 22(3):631-7. PubMed ID: 12579318
[TBL] [Abstract][Full Text] [Related]
16. Antitumor activity of humanized monoclonal antibody against HM1.24 antigen in human myeloma xenograft models.
Kawai S; Yoshimura Y; Iida S; Kinoshita Y; Koishihara Y; Ozaki S; Matsumoto T; Kosaka M; Yamada-Okabe H
Oncol Rep; 2006 Feb; 15(2):361-7. PubMed ID: 16391855
[TBL] [Abstract][Full Text] [Related]
17. Canonical nuclear factor kappaB pathway inhibition blocks myeloma cell growth and induces apoptosis in strong synergy with TRAIL.
Romagnoli M; Desplanques G; Maïga S; Legouill S; Dreano M; Bataille R; Barillé-Nion S
Clin Cancer Res; 2007 Oct; 13(20):6010-8. PubMed ID: 17947462
[TBL] [Abstract][Full Text] [Related]
18. Functional B7.2 and B7-H2 molecules on myeloma cells are associated with a growth advantage.
Yamashita T; Tamura H; Satoh C; Shinya E; Takahashi H; Chen L; Kondo A; Tsuji T; Dan K; Ogata K
Clin Cancer Res; 2009 Feb; 15(3):770-7. PubMed ID: 19188146
[TBL] [Abstract][Full Text] [Related]
19. Melan-A/MART1 analog peptide triggers anti-myeloma T-cells through crossreactivity with HM1.24.
Christensen O; Lupu A; Schmidt S; Condomines M; Belle S; Maier A; Hose D; Neuber B; Moos M; Kleist C; Terness P; Ho AD; Goldschmidt H; Klein B; Hundemer M
J Immunother; 2009; 32(6):613-21. PubMed ID: 19483648
[TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo activity of the maytansinoid immunoconjugate huN901-N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-maytansine against CD56+ multiple myeloma cells.
Tassone P; Gozzini A; Goldmacher V; Shammas MA; Whiteman KR; Carrasco DR; Li C; Allam CK; Venuta S; Anderson KC; Munshi NC
Cancer Res; 2004 Jul; 64(13):4629-36. PubMed ID: 15231675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
